• Event Type: The document is a regulatory filing enclosing the transcript of an Investor and Analyst Conference Call held to discuss the company's financial performance for Q2 and H1 FY27.
  • Event Date and Time: The conference call was held on November 6, 2026, at 2:00 PM IST.
  • Purpose of Event: The primary purpose was to discuss the Company's financial performance for the quarter and half year ended September 30, 2026.
  • Management Participants: The call featured Dr. Rajan Venkatesh (Managing Director and Chief Executive Officer), Mr. Amit Jain (Chief Financial Officer), and Mr. Harshvardhan Goenka (Executive Director and MD designate). The call was hosted by Strategic Growth Advisors.
  • UPSI Statement: The company explicitly stated that "No Unpublished Price Sensitive Information was shared or discussed during the call."
  • Financial Period Discussed: The call focused on the results for Q2 FY27 (Quarter ended September 30, 2026) and H1 FY27 (Half Year ended September 30, 2026).
  • Key Financial Highlights:
  • Q2 FY27 Revenue: Stood at INR 10,827 million, growing 55% year-on-year.
  • Q2 FY27 EBITDA: Stood at INR 1,080 million, representing 191% year-on-year growth.
  • Volume Growth: The growth was driven by strong double-digit volume growth and higher price realization.
  • H1 Performance: The company recorded its highest revenue volume and EBITDA for a first half.
  • Debt: Term debt as of September 30, 2026, stands at approximately INR 610 crores, with a net debt-to-equity ratio of 0.28x.
  • ROCE: Improved from 4.9% last year to 10.3% on a trailing 12-month basis.
  • Business Unit Performance:
  • Specialties Business: Revenue stood at INR 2,486 million, growing 36% YoY. EBITDA margins were impacted by higher fixed costs from the new Dahej facility startup and lag in passing through raw material cost increases in long-term contracts.
  • Essentials Business: Revenue stood at INR 8,341 million, growing 61% YoY, driven by double-digit volume growth and agile pricing actions.
  • Strategic and Operational Updates:
  • Leadership Transition: Dr. Rajan Venkatesh is stepping down, and Mr. Harshvardhan Goenka will succeed him as MD & CEO effective November 14, 2026.
  • Project Commissioning: The Dahej Project Phase II (Diketene derivatives) was partially commissioned in Q2, with remaining facilities expected in the coming quarter. The Lote Ethyl Acetate facility has been commissioned.
  • Project Vaayu: The investment undertaken with Hitachi remains on track for commissioning in Q3 FY27.
  • Market Context: Management highlighted a volatile operating environment with raw material price swings and supply chain disruptions due to geopolitical tensions and typhoons in Southeast Asia.

Additional Notes Section

  • Attachments: The regulatory filing enclosed the full transcript of the earnings conference call.
  • Delay in Submission: The company acknowledged a delay in submitting the transcript due to an "inadvertent administrative oversight" and has requested the stock exchanges to take a lenient view and condone the delay without penalty.
  • Financial Data: Significant financial data was disclosed and summarized in the transcript, including revenue, EBITDA, business unit breakdowns, debt levels, and ROCE.